This HTML5 document contains 60 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n14http://linked.opendata.cz/resource/domain/vavai/vysledek/RIV%2F60162694%3AG44__%2F14%3A43875252%21RIV15-MO0-G44_____/
dctermshttp://purl.org/dc/terms/
n21http://localhost/temp/predkladatel/
n20http://purl.org/net/nknouf/ns/bibtex#
n9http://linked.opendata.cz/resource/domain/vavai/riv/tvurce/
n17http://linked.opendata.cz/ontology/domain/vavai/
n13https://schema.org/
shttp://schema.org/
skoshttp://www.w3.org/2004/02/skos/core#
rdfshttp://www.w3.org/2000/01/rdf-schema#
n3http://linked.opendata.cz/ontology/domain/vavai/riv/
n18http://bibframe.org/vocab/
n2http://linked.opendata.cz/resource/domain/vavai/vysledek/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n4http://linked.opendata.cz/ontology/domain/vavai/riv/klicoveSlovo/
n5http://linked.opendata.cz/ontology/domain/vavai/riv/duvernostUdaju/
xsdhhttp://www.w3.org/2001/XMLSchema#
n12http://linked.opendata.cz/ontology/domain/vavai/riv/jazykVysledku/
n11http://linked.opendata.cz/ontology/domain/vavai/riv/aktivita/
n15http://linked.opendata.cz/ontology/domain/vavai/riv/druhVysledku/
n7http://linked.opendata.cz/ontology/domain/vavai/riv/obor/
n16http://reference.data.gov.uk/id/gregorian-year/

Statements

Subject Item
n2:RIV%2F60162694%3AG44__%2F14%3A43875252%21RIV15-MO0-G44_____
rdf:type
skos:Concept n17:Vysledek
rdfs:seeAlso
http://www.eurekaselect.com/123794/chapter
dcterms:description
Alzheimer's disease (AD) is a multifactorial disorder and apparently involves several different etiopathogenetic mechanisms. Up-to-date, there are no curative treatments or effective disease modifying therapies for AD. A strategy to enhance the cholinergic transmission by using acetylcholinesterase inhibitors (AChEIs) has been proposed more than two decades ago. Food and Drug Administration (FDA) gradually marketed these AChEIs: tacrine (1993), donepezil (1997), rivastigmine (2000) and galantamine (2001); tacrine is no longer used because of its high prevalence of hepatotoxicity. In addition to the AD cholinergic hypothesis , there is great evidence that voltage-gated, uncompetitive, N-methyl-D-aspartate (NMDA) antagonist memantine with moderate affinity can protect neurons from excitotoxicity. It was approved by FDA for treatment of moderate to severe stages of AD in 2003. Beyond symptomatic approaches there are anti-amyloid, neuroprotective and neuron-restorative strategies that hold promise of redefining the course of the disease as it is known. This contribution summarizes the main symptomatic strategies available for treating AD and future perspectives of pharmacotherapy for improving the AD course. Alzheimer's disease (AD) is a multifactorial disorder and apparently involves several different etiopathogenetic mechanisms. Up-to-date, there are no curative treatments or effective disease modifying therapies for AD. A strategy to enhance the cholinergic transmission by using acetylcholinesterase inhibitors (AChEIs) has been proposed more than two decades ago. Food and Drug Administration (FDA) gradually marketed these AChEIs: tacrine (1993), donepezil (1997), rivastigmine (2000) and galantamine (2001); tacrine is no longer used because of its high prevalence of hepatotoxicity. In addition to the AD cholinergic hypothesis , there is great evidence that voltage-gated, uncompetitive, N-methyl-D-aspartate (NMDA) antagonist memantine with moderate affinity can protect neurons from excitotoxicity. It was approved by FDA for treatment of moderate to severe stages of AD in 2003. Beyond symptomatic approaches there are anti-amyloid, neuroprotective and neuron-restorative strategies that hold promise of redefining the course of the disease as it is known. This contribution summarizes the main symptomatic strategies available for treating AD and future perspectives of pharmacotherapy for improving the AD course.
dcterms:title
Pharmacotherapy of Alzheimer's disease: current state and future perspectives Pharmacotherapy of Alzheimer's disease: current state and future perspectives
skos:prefLabel
Pharmacotherapy of Alzheimer's disease: current state and future perspectives Pharmacotherapy of Alzheimer's disease: current state and future perspectives
skos:notation
RIV/60162694:G44__/14:43875252!RIV15-MO0-G44_____
n3:aktivita
n11:I
n3:aktivity
I
n3:dodaniDat
n16:2015
n3:domaciTvurceVysledku
n9:8866651 n9:7895054 n9:1022989 n9:5586747 n9:4185137 n9:6306888
n3:druhVysledku
n15:C
n3:duvernostUdaju
n5:S
n3:entitaPredkladatele
n14:predkladatel
n3:idSjednocenehoVysledku
36385
n3:idVysledku
RIV/60162694:G44__/14:43875252
n3:jazykVysledku
n12:eng
n3:klicovaSlova
statins; metal chelators; M1 agonists; modulators of secretases; memantine; rivastigmine; galantamine; donepezil; tacrine; inhibitors; butyrylcholinesterase; acetylcholinesterase; Alzheimer's disease
n3:klicoveSlovo
n4:metal%20chelators n4:Alzheimer%27s%20disease n4:tacrine n4:statins n4:modulators%20of%20secretases n4:M1%20agonists n4:memantine n4:donepezil n4:butyrylcholinesterase n4:galantamine n4:rivastigmine n4:acetylcholinesterase n4:inhibitors
n3:kontrolniKodProRIV
[EABBE3BDC002]
n3:mistoVydani
Sharjah
n3:nazevZdroje
Frontiers in Drug Design & Discovery. Volume 6
n3:obor
n7:FR
n3:pocetDomacichTvurcuVysledku
6
n3:pocetStranKnihy
766
n3:pocetTvurcuVysledku
8
n3:rokUplatneniVysledku
n16:2014
n3:tvurceVysledku
Jun, Daniel Soukup, Ondřej Musílek, Kamil Zemek, Filip Nepovimová, Eugenie Korábečný, Jan Kuča, Kamil Špilovská, Katarína
s:numberOfPages
37
n18:doi
10.2174/9781608058228114060003
n20:hasPublisher
Bentham Science Publishers
n13:isbn
978-1-60805-822-8
n21:organizacniJednotka
G44